COVID-19 Shows US FDA Why It Needs To Know Supply Chain’s Current And Surge Capacities
Executive Summary
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.
You may also be interested in...
The Quality Lowdown: What Happens When The US FDA Must Choose Between Risks
Tuberculosis or cancer, sterility assurance or shortages, the choices come at you fast; Takeda, Wintac, Banco Vida updates.
Hospitals Struggle To Supply COVID-19 Teams With The Medicines They Need
Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.
Supply Chain Resilience Measures Included In Senate Coronavirus Bill
Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.